« Return to News | R&D Trends | Drug Sponsors

Flagship and Merck to foster early-stage life sciences innovation

Wednesday, April 11, 2012 12:37 PM

Flagship Ventures, a venture capital firm focused on healthcare and sustainability, has partnered with Merck Research Laboratories (MRL) and its newly formed Merck Research Ventures Fund to back new ventures that apply scientific breakthroughs to the development of new drugs in areas of unmet medical need.

Through the alliance, MRL will gain exposure to the investment and venture creation model that Flagship Ventures has applied over the last decade to successfully translate scientific innovation into medical breakthroughs. This partnership will also provide Flagship direct access to a global pharmaceutical industry leader with deep insight into pharmaceutical development, commercialization and regulation.

"Disruptive innovations increasingly derive from collaborations that can connect market insights, development expertise and scientific/technological breakthroughs," said Noubar Afeyan, managing partner and CEO of Flagship Ventures. "We are very excited that Merck is joining our growing network of academic and industry partners that support our firm and community of over 35 life science ventures."

As part of the collaboration, Merck Research Ventures Fund became an investor in Flagship Ventures Fund IV L.P., a $270 million oversubscribed venture capital fund closed in January 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.